# A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer

> **NCT06503497** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **BIOLOGICAL:** chemotherapy sequential CAR-NK cell infusion

## Key facts

- **NCT ID:** NCT06503497
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503497, "A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06503497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*